Sakar Healthcare Peer Comparison

NSE: SAKAR

₹1,006.95

₹21.15 (2.15%)

As on 03-Sep-2026 15:59IST

Market cap

₹2,240 Cr

Revenue (TTM)

₹272 Cr

P/E Ratio

62.1

P/B Ratio

6.7

Div. Yield

0 %

Edit

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	2,240	21,256	21,609	18,069	17,367
Revenue (₹ Cr)	272	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	36.10	735.15	678.07	666.92	169.62
Net Margin (%)	13.11	26.88	28.10	20.60	6.90
RoE (%)	11.50	19.16	19.73	18.75	20.76
Price to Earnings	62.07	28.91	32.48	28.06	102.39
Price-To-Book	6.69	4.82	5.74	4.47	19.21

Income Statement (₹ Cr)

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	271.97	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	275.41	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	194.54	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	77.43	941.63	796.58	1,139.61	229.86
Depreciation	24.54	57.58	78.10	281.06	17.24
EBIT	52.90	884.05	718.48	858.55	212.62
Interest	7.38	7.69	0.88	190.64	5.72
Other Income	3.44	165.62	125.96	7.45	26.48
Exceptional Items	0.00	-49.16	0.00	-17.24	-5.13
Profit before Tax	48.95	992.82	843.56	658.12	228.25
Provision for Tax	12.85	257.67	165.49	-8.80	58.63
Profit after Tax	36.10	735.15	678.07	666.92	169.62

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	324.45	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	47.02	91.50	28.74	1,392.75	134.50
Current Liabilities	109.54	627.48	385.94	2,077.10	981.81
Total Liabilities	415.26	4,911.11	3,207.85	6,865.52	1,879.19

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	330.75	770.28	1,291.22	5,617.77	42.47
Current Assets	140.46	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	415.26	4,911.11	3,207.85	6,865.52	1,879.19
Total Debt*	86.37	2.50	0.55	2,421.66	0.00
Net Current Assets	30.92	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	--	363.79	0.64	51.96	98.41

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	34.03	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	-30.71	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	-3.48	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	-0.16	383.07	59.32	103.72	30.57

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	8.43	26.21	26.22	13.59	21.29
ROE (%)	11.50	19.16	19.73	18.75	20.76
ROA (%)	8.06	14.95	18.69	9.26	9.67
EBIT Margin (%)	19.45	34.40	31.41	26.58	8.74
Net Margin (%)	13.11	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	43.77	10.69	15.01	9.59	31.10
EBIT Growth (%)	74.62	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	82.69	-9.09	19.61	62.68	-7.49
EPS Growth (%)	80.01	14.40	17.73	67.41	-18.33
Book Value Growth (%)	9.73	17.30	23.77	10.19	7.70

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	62.06	27.55	32.48	27.38	100.08
Price / Book Value	6.69	4.82	5.74	4.47	19.21
Dividend Yield (%)	0.00	1.61	0.14	0.55	0.52
EV/EBITDA	30.05	19.27	26.44	17.82	73.60
Market Cap (₹ Cr)	464.72	18,318.10	15,219.80	19,292.77	21,515.93

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.10	0.00	0.00	0.24	0.00
Short term debt to equity ratio	0.07	0.00	0.00	0.14	--
Current Ratio	1.28	6.06	6.70	0.74	1.77
Quick Ratio	0.64	5.31	5.59	0.53	0.73
Interest Coverage	7.63	130.11	959.59	4.45	40.90

	Sakar Healthcare	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	18.41	7.07	36.10	21.07	8.79
Asset Turnover	0.61	0.52	0.63	0.45	1.39
Receivable days	53.06	29.10	110.70	54.06	35.81
Inventory Days	73.30	69.53	65.86	32.16	82.25
Payable days	107.64	76.77	105.88	140.91	124.39
Cash Conversion Cycle	18.72	21.86	70.68	-54.69	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.